Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer

Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer - Personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002746

Enrollment

Registered

2009-11-11

Start date

2003-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castration-resistant prostate cancer

Interventions

patient-oriented peptide vaccinations for patients with castration resistant prostate cancer

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Castration resistant prostate cancer HLA-A2 or -A24 positive 100 % informed consent PS(ECOG):0 or 1 Life expectancy:more than 3 months Wash out: more than 4 weeks

Exclusion criteria

Exclusion criteria: Any of other cancers Infections (ex. HBV, HCV, HIV) Other serious disorders (ex. heart, lung, pulmonary, kidney, allergic diseases)

Design outcomes

Primary

Measure	Time frame
Toxicity evaluation.	—

Secondary

Measure	Time frame
Immunological and clinical responses	—

Countries

Japan

Contacts

Public ContactHirotsugu Uemura

Kinki University School of Medicine Urology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026